Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash from Operations (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Cash from Operations for 4 consecutive years, with 14550000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 6.2% to 14550000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 60231000.0, a 25.5% decrease, with the full-year FY2024 number at 50558000.0, down 9.61% from a year prior.
  • Cash from Operations was 14550000.0 for Q3 2025 at Orchestra BioMed Holdings, up from 15527000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 5324000.0 in Q1 2022 to a low of 16616000.0 in Q1 2025.
  • A 4-year average of 11511133.33 and a median of 10974000.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: tumbled 170.12% in 2023, then rose 8.81% in 2024.
  • Orchestra BioMed Holdings' Cash from Operations stood at 8744000.0 in 2022, then fell by 25.5% to 10974000.0 in 2023, then fell by 23.36% to 13538000.0 in 2024, then decreased by 7.48% to 14550000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Cash from Operations are 14550000.0 (Q3 2025), 15527000.0 (Q2 2025), and 16616000.0 (Q1 2025).